Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant Inc (NQ: IMVT )

39.19 -1.08 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 972,778
Open 39.63
Bid (Size) 38.00 (10)
Ask (Size) 40.50 (10)
Prev. Close 40.27
Today's Range 38.57 - 40.26
52wk Range 14.05 - 44.19
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Immunovant
Via Benzinga
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities

Performance

YTD
+109.01%
+109.01%
1 Month
+17.37%
+17.37%
3 Month
+68.05%
+68.05%
6 Month
+85.47%
+85.47%
1 Year
+161.79%
+161.79%

More News

Read More
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Where Immunovant Stands With Analysts
Via Benzinga
Recap: Immunovant Q2 Earnings
Via Benzinga
The Latest Analyst Ratings for Immunovant
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
Via Benzinga
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
Via Investor's Business Daily
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
Via Investor Brand Network
What's Going On Pfizer's Subsidiary Biohaven Stock?
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
Via The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
Via Talk Markets
Why Shares of Immunovant Are Soaring on Tuesday
Via The Motley Fool
Nasdaq Down 1.5%; Immunovant Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Moves Higher; Cintas Earnings Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.